Barclays Reiterates Sell Rating on Illumina, Inc.
Barclays maintains its sell rating on Illumina, Inc. with a price target of $145, a 17.87% downside from the current price.
Key Points
- Barclays reiterated its sell rating on Illumina, Inc. (ILMN) with a $145 price target on June 24, 2026.
- Barclays's $145 price target implies 17.87% downside from Illumina, Inc.'s ($ILMN) current $176.55 share price.
- Illumina shares traded around $164.93 on Wednesday, with a market cap of $24.42 billion and a P/E ratio of 29.29.
- BlackRock, Inc. increased its stake in Illumina by 701,913 shares, while Capital World Investors reduced its holdings by over 4.5 million shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barclays reiterated its sell rating on Illumina, Inc. (NasdaqGS: ILMN) with a price target of $145. This update from analyst Luke Sergott was made on June 24, 2026. Shares of Illumina traded near $164.93 on Wednesday.
Barclays vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Illumina, Inc. Stock Down 18.1%
On Wednesday, Illumina's shares were trading around $164.93. The company, which operates in the healthcare sector under diagnostics and research, has a market capitalization of approximately $24.42 billion. Its price-to-earnings (P/E) ratio stands at 29.29, with a forward P/E of 27.20. Illumina's stock has seen a 52-week low of $88.00 and a high of $177.22. It has a 50-day moving average of $144.57 and a 200-day moving average of $126.71. The company's current ratio is 1.75, and its quick ratio is 1.23, with a debt-to-equity ratio of 95.07.
$ILMN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Illumina reported revenue of approximately $4.39 billion, showing a growth of 4.8%. The company has a net margin of 19.42% and a return on equity (ROE) of 33.82%. The next earnings report is scheduled for July 30, 2026.
Insider Buying and Selling at Illumina, Inc.
Recent insider transactions at Illumina include a buy by Daniel Skovronsky, who purchased 1,674 shares at an average price of $164.28 on June 16, 2026. On the selling side, Patricia Leckman, the SVP and Chief People Officer, sold a total of 1,567 shares in planned transactions on June 2 and June 5. Keith Meister sold 235,000 shares on June 1, not under a planned program.
Analysts Set New Price Targets
On June 24, 2026, Barclays maintained a sell rating on Illumina with a $145 price target. Earlier, on June 10, 2026, JP Morgan upgraded Illumina to a buy with a $185 target. Guggenheim maintained its buy rating with a $180 target on June 1, 2026. The consensus among 18 analysts is a buy rating, with a mean price target of $148.56.
About Illumina, Inc.
Illumina, Inc., headquartered in San Diego, California, provides sequencing and array-based solutions for genetic and genomic analysis. The company serves a variety of clients, including research centers, academic institutions, and hospitals, as well as pharmaceutical and biotechnology companies. Illumina offers a range of products and services, including whole-genome sequencing kits and noninvasive prenatal testing. Led by CEO Jacob Thaysen, Illumina employs around 8,600 people.
Bottom Line
Barclays' reiteration of its sell rating for Illumina, Inc. highlights ongoing scrutiny from analysts. Investors track these ratings closely as they can influence market sentiment. It’s important to remember that analyst ratings like these are based on past and current data and may not reflect future performance.
Get Illumina, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ILMN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.